I-Mab Biopharma Expands Collaboration with Wuxi Biologics for three more Antibody Programs
Shots:
- I-Mab plans to license WuxiBody a proprietary platform from Wuxi for the development of three bispecific antibodies with focus on immuno-oncology and auto-immune
- This colloboration is the expansion of 2017 agreement between the companies which was intended for development and manufacturing of I-Mab pipeline products
- WuXiBody bispecifics have achieved 16g/L in cell culture titer- 95+% purity after one-step Protein A purification and 95+% yield for Protein A step
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
